Humacyte 배당금

배당금 기준 확인 0/6

Humacyte 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-6.6%

환매 수익률

총 주주 수익률	-6.6%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14

Humacyte: Intriguing Potential

Oct 13

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Aug 12

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 HUMA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: HUMA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Humacyte 시장 대비 배당 수익률

HUMA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (HUMA)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.5%
업계 평균 (Biotechs)	2.2%
애널리스트 예측 (HUMA) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HUMA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HUMA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HUMA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: HUMA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Humacyte 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Humacyte Announces Presentation of Positive Results from V007 Phase 3 Av Access Clinical Trial At the American Society of Nephrology’S Kidney Week 2024

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Humacyte, Inc. Announces Allowance of U.S. Patent Covering BioVascular Pancreas

Price target increased by 20% to US$13.17

Key Executive notifies of intention to sell stock

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

New minor risk - Insider selling

Humacyte, Inc. Acellular Tissue Engineered Vessel Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Price target increased by 13% to US$9.30

Consensus revenue estimates increase by 13%

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week